<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31836">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974518</url>
  </required_header>
  <id_info>
    <org_study_id>9187-PG-2012</org_study_id>
    <nct_id>NCT01974518</nct_id>
  </id_info>
  <brief_title>Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus</brief_title>
  <official_title>A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uprety Shraddha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of rituximab alone vs combination
      of rituximab and cyclophosphamide in the treatment of pemphigus not responding adequately to
      routine medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Study the clinical efficacy of IV rituximab vs IV rituximab and IV cyclophosphamide combination for treatment of refractory pemphigus in terms of early and late end points as defined by the international pemphigus committee</measure>
    <time_frame>upto 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome measures being
Time taken for control of disease activity
Time taken for achievement of partial remission
Time taken for achievement of complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study the characteristics of B cell depletion and repopulation following IV rituximab and combination of IV cyclophosphamide with  IV rituximab.</measure>
    <time_frame>upto 9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Flowcytometric analysis of CD19+ve27-ve na√Øve B cells count, CD19+ve27+ve memory B cells count and CD24highCD38high transitional cell count will be performed at baseline, 3rd month, 6th month and  9th month.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To  study  the  difference  in  relapse  rate</measure>
    <time_frame>upto 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>to study the total cumulative dose of corticosteroids adminstered and adjuvants required among patients of the 2 treatment groups</measure>
    <time_frame>upto 9 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pemphigus</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inj Rituximab 1 gram IV given on day 0 and day 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of Rituximab and Cyclophosphamide IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab and Cyclophosphamide IV</intervention_name>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Combination of Rituximab and Cyclophosphamide IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the diagnosis of pemphigus based on clinical, histopathological and
             immunological features the following:

          -  Refractory disease defined as continuing extension of old lesions, development of new
             lesion, or failure of established lesions to begin to heal despite 3 weeks of therapy
             on 1.5 mg/kg/day of prednisolone or its equivalent with or without the concurrent use
             of cyclophosphamide 2mg/kg/day for 12 weeks or azathioprine 2.5 mg/kg/day for 12
             weeks. Patients who fail to respond to 6 DCP/DP are also considered as refractory
             disease.

        Exclusion Criteria:

          -  Infections- Hepatitis B, Hepatitis C, HIV, active tuberculosis or sepsis.

          -  Abnormal liver function tests and renal function tests

          -  Known cardiac arrhythmia or conduction abnormality

          -  Systolic ejection fraction &lt;40%

          -  Pregnancy and breast feeding

          -  Severely decreased bone marrow functions.

          -  Known history of bladder cancer or hemorrhagic cystitis

          -  Known allergy to cyclophosphamide

          -  Patients of reproductive age group who haven't completed their family

          -  Known hypersensitivity to murine proteins.

          -  Patients who do not consent for the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shraddha Uprety, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>PGIMER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunil Dogra, MBBS/MD/DNB</last_name>
    <phone>91-9855005941</phone>
    <email>sundogra@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanjeev Handa, MBBS/MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Post-graduate Institute of Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Dogra, MBBS/MD/DNB</last_name>
      <phone>91-9855005941</phone>
      <email>sundogra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Shraddha Uprety, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shraddha Uprety, MBBS</last_name>
      <phone>8727045588</phone>
      <email>maitreeye@gmail.com.com</email>
    </contact>
    <contact_backup>
      <last_name>h</last_name>
    </contact_backup>
    <investigator>
      <last_name>Haridaran Anand Shanmugham, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Uprety Shraddha</investigator_full_name>
    <investigator_title>Junior Resident</investigator_title>
  </responsible_party>
  <keyword>Pemphigus</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituximab and IV cyclophosphamide combination</keyword>
  <keyword>B cell re-population characteristics following Rituximab</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
